Featured Story | | | Friday, August 4, 2017 Bristol-Myers Squibb will pay $300 million upfront and up to $2 billion in biobucks for IFM Therapeutics and its new immuno-oncology approaches. |
|
|
| This week's sponsor is FierceBiotech. | | | FierceBiotech Executive Summit- London
Join FierceBiotech for our third annual Executive Summit in London. We'll gather the experts together to discuss innovation around R&D in the UK and look ahead to what's in store for 2018 with leaders in the field discussing trends in the industry. |
Top Stories Friday, August 4, 2017 The Senate has voted in quick succession to pass bills reauthorizing the FDA to collect fees from the industry and expanding access to unapproved medicines. President Trump is now set to sign the user fee bill into law, while the right-to-try legislation will go to the House. Friday, August 4, 2017 Aeterna Zentaris has accused its former CEO and general counsel of plotting secretly to buy its lead candidate. The tiny, floundering biotech made the claim in a statement disclosing legal action it has begun against the pair over alleged disclosures of confidential information. Friday, August 4, 2017 Eli Lilly's bid to bring a new class of migraine therapy to market has just been lifted by a second positive trial that sets up first-marketing applications next year. Friday, August 4, 2017 Veritas Genetics has bought Curoverse to dial up its genome data interpretation capabilities. The takeover combines two George Church, Ph.D., cofounded startups to create a company equipped to sequence and make sense of genomes at scale. Friday, August 4, 2017 Get set for even more competition in the hepatitis C space. AbbVie’s Mavyret picked up FDA approval on Thursday as an eight-week treatment regardless of genotype, becoming the first such drug with the indication. Thursday, August 3, 2017 In this week's EuroBiotech Report, Idorsia posts insomnia data, Chiesi dumps uniQure, Loxo buys Redx drug and more. Friday, August 4, 2017 GlaxoSmithKline will soon close its global neuroscience R&D hub located in Shanghai, Pfizer and Astellas have decided to discontinue research into Xtandi's usage in breast cancer, Daiichi Sankyo is offering $300 million to settle about 2,300 lawsuits around Benicar and other news items from Asia's pharma industry. Friday, August 4, 2017 Biogen poached Pfizer executive Villalobos to lead its medicinal sciences efforts, AstraZeneca made two new oncology hires after the Mystic fall, Moderna tapped an industry veteran previously with Novartis to oversee manufacturing. Plus more hirings, firings and retirings throughout the industry. Resources Sponsored By: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Presented By: MPI Research FierceBiotech interviews Dr. DeWit to discuss a common cause for drug development delays, and strategies to avoid these costly setbacks. Sponsored By: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Sponsored By: Veeva Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA FierceBiotech 2nd Drug Development Forum September 25-27, 2017 | Boston, MA Don’t Miss the Industry’s Premier IO Conference – The Immuno-Oncology Summit August 28 - September 1, 2017 | Boston, MA FierceBiotech Executive Summit- London October 2, 2017 | London |
